92 related articles for article (PubMed ID: 19381161)
1. A genetic polymorphism of matrix metalloproteinase 9 (MMP-9) affects the changes in circulating MMP-9 levels induced by highly active antiretroviral therapy in HIV patients.
Demacq C; Vasconcellos VB; Marcaccini AM; Gerlach RF; Machado AA; Tanus-Santos JE
Pharmacogenomics J; 2009 Aug; 9(4):265-73. PubMed ID: 19381161
[TBL] [Abstract][Full Text] [Related]
2. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
[TBL] [Abstract][Full Text] [Related]
3. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
Gonçalves FM; Jacob-Ferreira AL; Gomes VA; Casella-Filho A; Chagas AC; Marcaccini AM; Gerlach RF; Tanus-Santos JE
Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
[TBL] [Abstract][Full Text] [Related]
4. A functional matrix metalloproteinase (MMP)-9 polymorphism modifies plasma MMP-9 levels in subjects environmentally exposed to mercury.
Jacob-Ferreira AL; Passos CJ; Gerlach RF; Barbosa F; Tanus-Santos JE
Sci Total Environ; 2010 Sep; 408(19):4085-92. PubMed ID: 20554312
[TBL] [Abstract][Full Text] [Related]
5. Different circulating metalloproteinases profiles in women with migraine with and without aura.
Martins-Oliveira A; Speciali JG; Dach F; Marcaccini AM; Gonçalves FM; Gerlach RF; Tanus-Santos JE
Clin Chim Acta; 2009 Oct; 408(1-2):60-4. PubMed ID: 19627981
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
[TBL] [Abstract][Full Text] [Related]
8. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy.
Marcaccini AM; Novaes AB; Meschiari CA; Souza SL; Palioto DB; Sorgi CA; Faccioli LH; Tanus-Santos JE; Gerlach RF
Clin Chim Acta; 2009 Nov; 409(1-2):117-22. PubMed ID: 19751716
[TBL] [Abstract][Full Text] [Related]
9. Functional matrix metalloproteinase (MMP)-9 genetic variants modify the effects of hemodialysis on circulating MMP-9 levels.
Marson BP; Lacchini R; Belo V; Mattos SG; da Costa BP; Poli-de-Figueiredo CE; Tanus-Santos JE
Clin Chim Acta; 2012 Dec; 414():46-51. PubMed ID: 23010359
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-9 genetic variations affect MMP-9 levels in obese children.
Belo VA; Souza-Costa DC; Luizon MR; Lanna CM; Carneiro PC; Izidoro-Toledo TC; Ferraz KC; Tanus-Santos JE
Int J Obes (Lond); 2012 Jan; 36(1):69-75. PubMed ID: 21844877
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphism c.1562C>T of the MMP-9 is associated with macroangiopathy in type 2 diabetes mellitus.
Wang Y; Su Y; Xu Y; Pan SH; Liu GD
Biochem Biophys Res Commun; 2010 Jan; 391(1):113-7. PubMed ID: 19909726
[TBL] [Abstract][Full Text] [Related]
12. Circulating matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases-1 and -2 levels in gestational hypertension.
Tayebjee MH; Karalis I; Nadar SK; Beevers DG; MacFadyen RJ; Lip GY
Am J Hypertens; 2005 Mar; 18(3):325-9. PubMed ID: 15797648
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
[TBL] [Abstract][Full Text] [Related]
14. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension.
Palei AC; Sandrim VC; Cavalli RC; Tanus-Santos JE
Clin Biochem; 2008 Jul; 41(10-11):875-80. PubMed ID: 18477480
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase-9 polymorphisms affect plasma MMP-9 levels and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.
Palei AC; Sandrim VC; Amaral LM; Machado JS; Cavalli RC; Lacchini R; Duarte G; Tanus-Santos JE
Pharmacogenomics J; 2012 Dec; 12(6):489-98. PubMed ID: 21769110
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects.
Demacq C; de Souza AP; Machado AA; Gerlach RF; Tanus-Santos JE
Clin Chim Acta; 2006 Mar; 365(1-2):183-7. PubMed ID: 16168399
[TBL] [Abstract][Full Text] [Related]
17. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
[TBL] [Abstract][Full Text] [Related]
18. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
19. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
[TBL] [Abstract][Full Text] [Related]
20. Increased acinar damage of salivary glands of patients with Sjögren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios.
Pérez P; Kwon YJ; Alliende C; Leyton L; Aguilera S; Molina C; Labra C; Julio M; Leyton C; González MJ
Arthritis Rheum; 2005 Sep; 52(9):2751-60. PubMed ID: 16142742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
